Drug Profile
MDX 214
Alternative Names: Anti-EGFr/CD89 antibody; MDX-214Latest Information Update: 03 May 2007
Price :
$50
*
At a glance
- Originator Medarex
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Epidermal growth factor inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 03 May 2007 Discontinued - Phase-I/II for Cancer in USA (unspecified route)
- 05 Aug 2005 This compound is still in active development - (BIO-2005)
- 23 Apr 2004 Phase-I/II clinical trials in Cancer in USA (unspecified route)